Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

RH Jones; K Fizazi; ND James; TL Tammela; N Matsubara; F Priou; P Beuzeboc; T Lesimple; P Bono; V Kataja; JA Garcia; A Protheroe; N Shore; J Aspegren; H Joensuu; I Kuss; S Fiala-Buskies; Egils Vjaters

doi:10.1038/s41391-023-00740-9

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

RH Jones (Corresponding Author)
, K Fizazi
, ND James
, TL Tammela
, N Matsubara
, F Priou
, P Beuzeboc
, T Lesimple
, P Bono
, V Kataja
, JA Garcia
, A Protheroe
, N Shore
, J Aspegren
, H Joensuu
, I Kuss
, S Fiala-Buskies
, Egils Vjaters

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	786–789
Number of pages	4
Journal	Prostate Cancer and Prostatic Diseases
Volume	27
DOIs	https://doi.org/10.1038/s41391-023-00740-9
Publication status	Published - 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1038/s41391-023-00740-9Licence: CC BY

Safety and tolerability of long-term treatmentFinal published version, 360 KBLicence: CC BY

https://www.nature.com/articles/s41391-023-00740-9#citeasLicence: CC BY

Cite this

Jones, RH., Fizazi, K., James, ND., Tammela, TL., Matsubara, N., Priou, F., Beuzeboc, P., Lesimple, T., Bono, P., Kataja, V., Garcia, JA., Protheroe, A., Shore, N., Aspegren, J., Joensuu, H., Kuss, I., Fiala-Buskies, S., & Vjaters, E. (2024). Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 27, 786–789. https://doi.org/10.1038/s41391-023-00740-9

@article{15ac9c380e98433493b3adf1dffa9525,

title = "Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer",

author = "RH Jones and K Fizazi and ND James and TL Tammela and N Matsubara and F Priou and P Beuzeboc and T Lesimple and P Bono and V Kataja and JA Garcia and A Protheroe and N Shore and J Aspegren and H Joensuu and I Kuss and S Fiala-Buskies and Egils Vjaters",

year = "2024",

doi = "10.1038/s41391-023-00740-9",

language = "English",

volume = "27",

pages = "786–789",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

}

Jones, RH, Fizazi, K, James, ND, Tammela, TL, Matsubara, N, Priou, F, Beuzeboc, P, Lesimple, T, Bono, P, Kataja, V, Garcia, JA, Protheroe, A, Shore, N, Aspegren, J, Joensuu, H, Kuss, I, Fiala-Buskies, S & Vjaters, E 2024, 'Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer', Prostate Cancer and Prostatic Diseases, vol. 27, pp. 786–789. https://doi.org/10.1038/s41391-023-00740-9

TY - JOUR

T1 - Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

AU - Jones, RH

AU - Fizazi, K

AU - James, ND

AU - Tammela, TL

AU - Matsubara, N

AU - Priou, F

AU - Beuzeboc, P

AU - Lesimple, T

AU - Bono, P

AU - Kataja, V

AU - Garcia, JA

AU - Protheroe, A

AU - Shore, N

AU - Aspegren, J

AU - Joensuu, H

AU - Kuss, I

AU - Fiala-Buskies, S

AU - Vjaters, Egils

PY - 2024

Y1 - 2024

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:001096093100001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1038/s41391-023-00740-9

DO - 10.1038/s41391-023-00740-9

M3 - Article

C2 - 37884613

SN - 1365-7852

VL - 27

SP - 786

EP - 789

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

ER -

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this